Frijlink H W, Eissens A C, Hefting N R, Poelstra K, Lerk C F, Meijer D K
Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, The Netherlands.
Pharm Res. 1991 Jan;8(1):9-16. doi: 10.1023/a:1015861719134.
The inclusion complex formation of intravenously administered hydroxypropyl-beta-cyclodextrin and beta-cyclodextrin with endogenous lipids was studied. We tested the hypothesis that complex formation of endogenous cholesterol with cyclodextrins in the bloodstream leads to extraction of cholesterol from the large lipoprotein particles. The relatively small cholesterol-cyclodextrin complexes then leave the bloodstream via capillary pores, and dissociation of the complex in the extravascular compartment finally causes redistribution of cholesterol from blood to tissue. This hypothesis is supported by the following experimental findings. Intravenous administration of cyclodextrins led to a transient decrease in plasma cholesterol levels in a dose-dependent manner, and in vitro cholesterol-cyclodextrin complexes passed dialysis membranes with a molecular weight cutoff of 6000-8000. Further, cyclodextrins increased protein binding of the steroidal drug spironolactone, probably through removal of cholesterol from plasma protein binding sites. Finally, extravascular redistribution was directly demonstrated in histological studies of the kidneys. Glomerular filtration of the cholesterol-cyclodextrin complex is followed by dissociation of the complex in the ultrafiltrate, resulting in cholesterol accumulation in the proximal tubule cells. The cholesterol-beta-cyclodextrin complex has a limited aqueous solubility. Crystallization of this complex in renal tissue might explain the nephrotoxicity of parenterally administered beta-cyclodextrin. The absence of such crystallization might explain the lower nephrotoxicity of hydroxypropyl-beta-cyclodextrin after intravenous administration.
研究了静脉注射羟丙基-β-环糊精和β-环糊精与内源性脂质形成包合物的情况。我们验证了这样一个假设:血液中内源性胆固醇与环糊精形成复合物会导致胆固醇从大脂蛋白颗粒中被提取出来。相对较小的胆固醇-环糊精复合物随后通过毛细血管孔离开血液,复合物在血管外间隙的解离最终导致胆固醇从血液重新分布到组织中。以下实验结果支持了这一假设。静脉注射环糊精会导致血浆胆固醇水平呈剂量依赖性短暂下降,并且体外胆固醇-环糊精复合物能够通过截留分子量为6000 - 8000的透析膜。此外,环糊精可能通过去除血浆蛋白结合位点上的胆固醇来增加甾体药物螺内酯的蛋白结合率。最后,在肾脏的组织学研究中直接证实了血管外再分布。胆固醇-环糊精复合物经肾小球滤过后,复合物在超滤液中解离,导致近端小管细胞内胆固醇蓄积。胆固醇-β-环糊精复合物的水溶性有限。这种复合物在肾组织中的结晶可能解释了胃肠外给药β-环糊精的肾毒性。静脉注射后羟丙基-β-环糊精肾毒性较低可能是由于没有这种结晶现象。